Email a Friend
Print ArticleOsteoporosis Health Center
Survey: Many Women Slip on Bone Health
May 14, 2009 -- Many postmenopausal women with osteoporosis are not on top of their disease management, according to a new national survey.
Osteoporosis has been declared a global health crisis by the World Health Organization and other health groups, and federal authorities say fractures related to osteoporosis are a major cause of death and disability.
More than 1,800 postmenopausal women completed online surveys conducted the last week of March 2009 by Harris Interactive and commissioned by the Know My Bones Council. Of the survey participants, 889 had postmenopausal osteoporosis and 912 didn’t, and all were 50 or older.
The survey found, among other things, that:
- 21% plan to retire later than expected. Half the women with osteoporosis surveyed are afraid their disease will limit their ability to work.
- Although 83% of women with osteoporosis believe they are doing all they can to manage their disease, women with osteoporosis were no more likely to know their bone density scores than women without the disease.
- 27% of the women with osteoporosis said they often don’t take their medication. Nearly half of these women say it is because they forget to take it.
- Only 35% of women with osteoporosis reported initiating a conversation with their doctors about the disease.
- 84% of the women with osteoporosis agree that women today have a greater need than previous generations to maintain an active lifestyle.
- 22% of women who planned to retire later than expected said the reason was to maintain health insurance benefits.
- 70% of women with osteoporosis fear they’ll lose independence because of the disease.
- 71% of the postmenopausal women with osteoporosis say they have suffered a fracture that has made them more careful about avoiding future fractures.
- 73% of women with osteoporosis who have suffered a fracture consider themselves a burden to their families, helpless, or feel they have lost independence.
The report says education can motivate women to make bone health a greater priority. After survey participants reviewed educational information about osteoporosis, nearly three quarters of women with osteoporosis reported that they plan to make their bone health more of a priority.
The Know My Bones Council includes the National Osteoporosis Foundation, the Society for Women’s Health Research, and Amgen, a company that manufactures medicines.
“As women retire later, bone health is not a luxury, it is a necessity,” says Felicia Cosman, MD, clinical director of the National Osteoporosis Foundation and medical director of the Clinical Research Center at Helen Hayes Hospital. “Although some women are making significant strikes toward better bone health, many are not and need to do more.”
Archelle Georgiou, MD, a member of the Society for Women’s Health Research board of directors, says that because four out of five people with osteoporosis are women, it’s critical for them to make healthy bones a priority effort.
“We are pleased to see that after learning about the risks of osteoporosis as part of the survey, many women reported that they would take action to make bone health more of a priority by speaking with their doctor, re-evaluating their bone density scores, and educating themselves and others,” she says in a news release.
May is Osteoporosis Awareness and Prevention Month.
del.icio.us
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.
Taking Vitamin D and Calcium Together
Osteoporosis specialist Dr. Ethel Siris on why it's so important to take calcium with Vitamin D.
